Vitalhub Corp. Missed EPS And Analysts Are Revising Their Forecasts

Vitalhub Corp. (TSE:VHI) shareholders are probably feeling a little disappointed, since its shares fell 6.8% to CA$10.22 in the week after its latest quarterly results. Revenues beat expectations by 12% to hit CA$32m, although earnings fell badly short, with Vitalhub reported a statutory loss of CA$0.01 per share even though the analysts had been forecasting a profit. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

TSX:VHI Earnings and Revenue Growth November 9th 2025

After the latest results, the eleven analysts covering Vitalhub are now predicting revenues of CA$127.2m in 2026. If met, this would reflect a major 30% improvement in revenue compared to the last 12 months. Per-share earnings are expected to leap 498% to CA$0.27. Before this earnings report, the analysts had been forecasting revenues of CA$125.2m and earnings per share (EPS) of CA$0.28 in 2026. So it looks like there’s been a small decline in overall sentiment after the recent results – there’s been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

See our latest analysis for Vitalhub

It might be a surprise to learn that the consensus price target was broadly unchanged at CA$15.34, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. The consensus price target is just an average of individual analyst targets, so – it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Vitalhub at CA$16.50 per share, while the most bearish prices it at CA$15.00. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Vitalhub is an easy business to forecast or the the analysts are all using similar assumptions.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Vitalhub’s revenue growth is expected to slow, with the forecast 23% annualised growth rate until the end of 2026 being well below the historical 34% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 11% annually. Even after the forecast slowdown in growth, it seems obvious that Vitalhub is also expected to grow faster than the wider industry.

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Vitalhub. Fortunately, they also reconfirmed their revenue numbers, suggesting that it’s tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates – from multiple Vitalhub analysts – going out to 2027, and you can see them free on our platform here.

And what about risks? Every company has them, and we’ve spotted 4 warning signs for Vitalhub you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Continue Reading